Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating

Multicentric, Randomized, Double Blind Study for Assessment of Efficacy and Tolerability of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02032862

Enrollment

107

Registered

2014-01-10

Start date

2013-12-31

Completion date

2015-07-31

Last updated

2015-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopausal Hot Flushes

Keywords

menopause, hot flushes, hot flashes, salvia, sage, sweating

Brief summary

Sage tablets ( 3400 mg extract from fresh sage leaves, DER 1:17) in a once daily application over 12 treatment weeks are compared against placebo in 200 menopausal patients with ≥ 5 hot flushes daily and a Hyperhidrosis Scale score ≥ 2

Interventions

DRUGSage extract, 3400 mg , DER 1:17

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

50 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Menopausal since ≥ 1 year * ≥ 5 hot flushes /24 hours * Hyperhidrosis Scale score ≥ 2

Exclusion criteria

* Affections like asthma, COPD, depression, diabetes, epilepsy, hyper- and hypothyreosis, malign tumours

Design outcomes

Primary

Measure	Time frame
Change from Baseline Hyperhidrosis Disease Severity Scale	Week 12

Secondary

Measure	Time frame
Change from Baseline Menopause Rating Scale / MRS	Week 12
Change from Baseline Modified Dem Tect	Week 12

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026